Franziska Eckert

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4665978/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer. Cancer Immunology, Immunotherapy, 2022, 71, 541-552.	4.2	8
2	Dynamics of HMBG1 (High Mobility Group Box 1) during radiochemotherapy correlate with outcome of HNSCC patients. Strahlentherapie Und Onkologie, 2022, 198, 194-200.	2.0	7
3	Frequent FGFR1 hotspot alterations in driver-unknown low-grade glioma and mixed neuronal-glial tumors. Journal of Cancer Research and Clinical Oncology, 2022, 148, 857-866.	2.5	7
4	Patientâ€individual phenotypes of glioblastoma stem cells are conserved in culture and associate with radioresistance, brain infiltration and patient prognosis. International Journal of Cancer, 2022, 150, 1722-1733.	5.1	8
5	Potassium Channels in Cancer. Handbook of Experimental Pharmacology, 2021, 267, 253-275.	1.8	6
6	Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. Biomolecules, 2021, 11, 1561.	4.0	8
7	Hypofractionated preoperative radiotherapy for high risk soft tissue sarcomas in a geriatric patient population. Radiology and Oncology, 2021, 55, 459-466.	1.7	5
8	Depatux-M and temozolomide in advanced high-grade glioma. Neuro-Oncology Advances, 2020, 2, vdaa063.	0.7	1
9	Perioperative strategy and outcome in giant retroperitoneal dedifferentiated liposarcoma—results of a retrospective cohort study. World Journal of Surgical Oncology, 2020, 18, 296.	1.9	12
10	Lymphocyte-Sparing Radiotherapy: The Rationale for Protecting Lymphocyte-rich Organs When Combining Radiotherapy With Immunotherapy. Seminars in Radiation Oncology, 2020, 30, 187-193.	2.2	57
11	Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy. Radiation Oncology, 2020, 15, 135.	2.7	8
12	Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial. BMC Cancer, 2020, 20, 557.	2.6	29
13	Against Repurposing Methadone for Glioblastoma Therapy. Biomolecules, 2020, 10, 917.	4.0	8
14	MR Thermometry Data Correlate with Pathological Response for Soft Tissue Sarcoma of the Lower Extremity in a Single Center Analysis of Prospectively Registered Patients. Cancers, 2020, 12, 959.	3.7	11
15	Diffusion kurtosis imaging histogram parameter metrics predicting survival in integrated molecular subtypes of diffuse glioma: An observational cohort study. European Journal of Radiology, 2019, 112, 144-152.	2.6	17
16	Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells. Cancers, 2019, 11, 110.	3.7	44
17	Oncogenic KRAS hotspot mutations are rare in IDHâ€mutant gliomas. Brain Pathology, 2019, 29, 321-324.	4.1	4
18	Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors. Frontiers in Immunology, 2019, 10, 407.	4.8	44

FRANZISKA ECKERT

#	Article	IF	CITATIONS
19	Retrospective analysis of fractionated intensity-modulated radiotherapy (IMRT) in the interdisciplinary management of primary optic nerve sheath meningiomas. Radiation Oncology, 2019, 14, 240.	2.7	25
20	Contrast enhancement predicting survival in integrated molecular subtypes of diffuse glioma: an observational cohort study. Journal of Neuro-Oncology, 2018, 139, 373-381.	2.9	14
21	Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model. Cancer Immunology, Immunotherapy, 2018, 67, 653-662.	4.2	11
22	Facing the Guilt and Commemorating the Victims: German Radiology and Radiation Oncology During National Socialism. Journal of the American College of Radiology, 2018, 15, 669-673.	1.8	4
23	Radiotherapy and hyperthermia with curative intent in recurrent high risk soft tissue sarcomas. International Journal of Hyperthermia, 2018, 34, 980-987.	2.5	11
24	Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer. Frontiers in Immunology, 2018, 9, 3018.	4.8	94
25	Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. Oncolmmunology, 2018, 7, e1496881.	4.6	33
26	Principles and Developments in Cancer Immunotherapy and Approaches for Combination with Tumour Irradiation. Progress in Tumor Research, 2018, , 1-10.	0.1	0
27	KCa3.1 Channels and Glioblastoma: In Vitro Studies. Current Neuropharmacology, 2018, 16, 627-635.	2.9	42
28	Standing on the ramp: A young German radiation oncologist faces her ancestors. Practical Radiation Oncology, 2017, 7, 293-294.	2.1	1
29	Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects <i>in vivo</i> . Oncolmmunology, 2017, 6, e1323161.	4.6	39
30	The Prognostic Impact of Ventricular Opening in Glioblastoma Surgery: A Retrospective Single Center Analysis. World Neurosurgery, 2017, 106, 615-624.	1.3	19
31	Reply to the Letter to the Editor by D. D'Arcangelo et al.: "lon Channels in Brain Metastasisâ€â€"Ion Channels in Cancer Set up and Metastatic Progression Ion Channels in Brain Metastasis. International Journal of Molecular Sciences, 2017, 18, 719.	4.1	0
32	Ion Channels in Brain Metastasis. International Journal of Molecular Sciences, 2016, 17, 1513.	4.1	26
33	Enhanced binding of necrosis-targeting immunocytokine NHS-IL12 after local tumour irradiation in murine xenograft models. Cancer Immunology, Immunotherapy, 2016, 65, 1003-1013.	4.2	26
34	ATRX immunostaining predicts IDH and H3F3A status in gliomas. Acta Neuropathologica Communications, 2016, 4, 60.	5.2	100
35	Nodal Clearance Rate and Long-Term Efficacy ofÂIndividualized Sentinel Node–Based Pelvic Intensity Modulated Radiation Therapy for High-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 94, 263-271.	0.8	6
36	Role of ion channels in ionizing radiation-induced cell death. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2657-2664.	2.6	23

FRANZISKA ECKERT

#	Article	IF	CITATIONS
37	Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation. Oncolmmunology, 2015, 4, e1014760.	4.6	49
38	Chronic graft-versus-host-disease in CD34+-humanized NSG mice is associated with human susceptibility HLA haplotypes for autoimmune disease. Journal of Autoimmunity, 2015, 62, 55-66.	6.5	38
39	Prospective evaluation of a hydrogel spacer for rectal separation in dose-escalated intensity-modulated radiotherapy for clinically localized prostate cancer. BMC Cancer, 2013, 13, 27.	2.6	39
40	lonizing radiation, ion transports, and radioresistance of cancer cells. Frontiers in Physiology, 2013, 4, 212.	2.8	55
41	Definitive radiotherapy and Single-Agent radiosensitizing Ifosfamide in Patients with localized, irresectable Soft Tissue Sarcoma: A retrospective analysis. Radiation Oncology, 2010, 5, 55.	2.7	29
42	SCLC extensive disease – treatment guidance by extent or/and biology of response?. Radiation Oncology, 2008, 3, 33.	2.7	9